202 related articles for article (PubMed ID: 11588528)
1. T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans.
Petrov VV; Fagard RH; Lijnen PJ
J Cardiovasc Pharmacol; 2001 Oct; 38(4):578-83. PubMed ID: 11588528
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with enalapril or losartan does not show antiproliferative effects in peripheral blood mononuclear cells.
Petrov VV; Fagard RH; Lijnen PJ
Methods Find Exp Clin Pharmacol; 2001 Apr; 23(3):149-52. PubMed ID: 11523315
[TBL] [Abstract][Full Text] [Related]
3. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
5. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
Byyny RL; Merrill DD; Bradstreet TE; Sweet CS
Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074
[TBL] [Abstract][Full Text] [Related]
6. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study.
Verdecchia P; Schillaci G; Reboldi GP; Sacchi N; Bruni B; Benemio G; Porcellati C
Blood Press Monit; 2000 Jun; 5(3):187-93. PubMed ID: 10915233
[TBL] [Abstract][Full Text] [Related]
9. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Goodfield NE; Newby DE; Ludlam CA; Flapan AD
Circulation; 1999 Jun; 99(23):2983-5. PubMed ID: 10368114
[TBL] [Abstract][Full Text] [Related]
10. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension.
Fagard R; Lijnen P; Pardaens K; Thijs L; Vinck W
J Hum Hypertens; 2001 Mar; 15(3):161-7. PubMed ID: 11317199
[TBL] [Abstract][Full Text] [Related]
11. Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers.
Vervoort G; Hertenberg F; Wetzels JF; Smits P
J Hypertens; 1998 Feb; 16(2):245-50. PubMed ID: 9535153
[TBL] [Abstract][Full Text] [Related]
12. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
Abe M; Okada K; Maruyama T; Matsumoto K
Int J Clin Pharmacol Ther; 2009 Aug; 47(8):525-32. PubMed ID: 19640361
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.
Fogari R; Zoppi A; Lazzari P; Preti P; Mugellini A; Corradi L; Lusardi P
J Cardiovasc Pharmacol; 1998 Oct; 32(4):616-20. PubMed ID: 9781930
[TBL] [Abstract][Full Text] [Related]
15. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man.
Yee KM; Struthers AD
Br J Clin Pharmacol; 1998 Dec; 46(6):583-8. PubMed ID: 9862248
[TBL] [Abstract][Full Text] [Related]
16. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats.
Otsuka S; Sugano M; Makino N; Sawada S; Hata T; Niho Y
Hypertension; 1998 Sep; 32(3):467-72. PubMed ID: 9740612
[TBL] [Abstract][Full Text] [Related]
17. Autonomic function and baroreflex sensitivity during angiotensin-converting enzyme inhibition or angiotensin II AT-1 receptor blockade in essential hypertensive patients.
Guasti L; Petrozzino MR; Mainardi LT; Grimoldi P; Zanotta D; Garganico D; Diolisi A; Simoni C; Grandi AM; Gaudio G; Cerutti S; Venco A
Acta Cardiol; 2001 Oct; 56(5):289-95. PubMed ID: 11712824
[TBL] [Abstract][Full Text] [Related]
18. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats.
Taylor K; Patten RD; Smith JJ; Aronovitz MJ; Wight J; Salomon RN; Konstam MA
J Cardiovasc Pharmacol; 1998 May; 31(5):654-60. PubMed ID: 9593063
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients.
Azizi M; Linhart A; Alexander J; Goldberg A; Menten J; Sweet C; Ménard J
J Hypertens; 2000 Aug; 18(8):1139-47. PubMed ID: 10954007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
